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Syndromes of Thrombotic Microangiopathy
To the Editor: In their review of the throm-
botic microangiopathy syndromes, George and 
Nester (Aug. 14 issue)1 do not mention the option 
of treating severe neurologic deficits in patients 
with shiga toxin–mediated hemolytic–uremic 
syndrome (ST-HUS) with IgG depletion through 
immunoadsorption.2 In the 2011 outbreak in 
northern Germany, the delay in the onset of neu-
rologic symptoms (5 to 12 days after the onset of 
diarrhea; mean and median, 8.0 days) strongly 
suggested antibody involvement in the pathogen-
esis of these symptoms. Consequently, all 12 pa-
tients had substantial improvement, and 10 of 
them fully recovered after IgG depletion through 
immunoadsorption, despite the failure of all oth-
er known treatments. This treatment option, al-
though based on one prospective, uncontrolled 
study, may be a lifesaving treatment and should 
be considered in similar cases.
Shraga Aviner, M.D., Ph.D. 
Haim Bibi, M.D.
Barzilai University Medical Center 
Ashkelon, Israel 
aviners@barzi.health.gov.il
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To the Editor: George and Nester mention the 
main causes and pathological and clinical fea-
tures of the thrombotic microangiopathy syn-
dromes, disorders that can also be associated 
with pneumococcal infection. The pathogenesis 
of this rare but severe complication probably im-
plicates the binding of the Thomsen–Friedenreich 
antigen to preformed circulating IgM antibodies, 
owing to the neuraminidase-mediated cleavage 
of sialic acid residues from the membrane of glo-
merular capillary endothelial cells, red cells, and 
platelets.1 Neuraminidase-associated thrombotic 
microangiopathy is generally observed in pediat-
ric patients with pneumonia and meningitis and 
rarely in those with isolated pneumococcal infec-
tion.2 The disease, frequently described as the 
hemolytic–uremic syndrome, has also been as-
sociated with group A beta-hemolytic streptococ-
cus infection.3 Furthermore, the true incidence 
of neuraminidase-associated thrombotic micro-
angiopathy could be underestimated.2 Pneumo-
coccal infection should be included among the 
causes of the thrombotic microangiopathy syn-
dromes and considered especially in pediatric 
patients.
Fabio Villa, M.D.
Ente Ospedaliero Cantonale 
Bellinzona, Switzerland 
fabiovilla210486@gmail.com
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To the Editor: George and Nester describe co-
balamin C deficiency as one underlying cause 
of thrombotic microangiopathies. On the basis of 
our experience with cobalamin C deficiency in 
these syndromes1 and the findings of other inves-
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tigators,2-4 we would like to emphasize three 
clinically relevant aspects. First, although a ma-
jority of patients with cobalamin C deficiency 
present in infancy with neurologic problems,4 
such deficiency in patients with thrombotic 
 microangiopathies is observed throughout child-
hood and adolescence.1-4 Second, since cobala-
min C deficiency is treatable and occurs in com-
bination with other causes of thrombotic 
microangiopathies (reported in four patients),1,2 
we advocate routine measurement of blood levels 
of homocysteine in all patients with thrombotic 
microangiopathies, including those with com-
plement defects. Homocysteine builds up as a 
result of renal failure,5 and values above 20 to 30 
μmol per liter warrant further workup to exclude 
cobalamin C deficiency. Third, among the vari-
ous coexisting clinical manifestations in cobala-
min C deficiency, particular care should be taken 
to rule out pulmonary hypertension, which is as-
sociated with renal thrombotic microangiopa-
thy1 and has a dismal outcome, especially when 
treatment is delayed.
Martin Kömhoff, M.D., Ph.D. 
Marcus T. Roofthooft, M.D., Ph.D. 
Francjan Spronsen, M.D., Ph.D.
University Medical Center Groningen 
Groningen, the Netherlands 
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The Authors Reply: Aviner and Bibi cite the re-
port of Greinacher et al. in which IgG depletion 
by means of immunoadsorption was used to 
treat patients with ST-HUS who had severe neu-
rologic sequelae.1 We agree that the recovery of 
the patients as described in their report was im-
pressive. We also agree that patients with severe 
neurologic sequelae may warrant a trial of less 
proven treatments. We noted in our article that it 
is uncertain whether plasma exchange or anti-
complement therapy is beneficial in patients with 
ST-HUS. We did not consider immunoadsorption 
because the existence of an antibody as the cause 
of neurologic sequelae in ST-HUS has not been 
documented.
Villa states that we should have considered 
thrombotic microangiopathy associated with se-
vere pneumococcal sepsis as a primary syndrome. 
We had considered this because studies frequent-
ly describe pneumococcal sepsis-mediated throm-
botic microangiopathy. However, we did not in-
clude it in our set of primary syndromes because 
of the limited mechanistic evidence that it is a 
distinct syndrome and because distinguishing 
this entity from the clinical manifestations of 
overwhelming sepsis is inherently difficult.
Kömhoff et al. advocate routine measurements 
of blood homocysteine levels in all patients pre-
senting with thrombotic microangiopathy to 
determine whether cobalamin C deficiency could 
be the cause. We agree. In our article, we noted 
a recent case report in which cobalamin C defi-
ciency was discovered to be the cause of throm-
botic microangiopathy with severe kidney injury, 
which allowed for effective treatment.2 However, 
discussion of the clinical evaluation of patients 
with thrombotic microangiopathy was beyond 
the scope of our review. Currently, many patients 
present with thrombotic microangiopathy and 
acute kidney injury without a clear cause. We 
believe that the wider use of routine laboratory 
assays (e.g., for plasma homocysteine and methi-
onine and urine methylmalonic acid) may reveal 
a previously unsuspected diagnosis with minimal 
cost and no risk to the patient.
James N. George, M.D.
University of Oklahoma Health Sciences Center 
Oklahoma City, OK 
james-george@ouhsc.edu
Carla M. Nester, M.D.
University of Iowa 
Iowa City, IA
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Case 25-2014: A Man with Ulcerative Colitis and Bloody 
Diarrhea
To the Editor: The Case Record contributed by 
Hohmann et al. (Aug. 14 issue),1 regarding a man 
with ulcerative colitis in whom bloody diarrhea 
developed soon after fecal microbiota transplan-
tation (FMT), highlights the difficulty in distin-
guishing cytomegalovirus (CMV) as a direct 
cause of disease from its being an “innocent by-
stander” in patients with CMV infection and ac-
tive ulcerative colitis. However, the authors also 
reported an apparent case of diarrheal disease 
caused by Blastocystis hominis transmitted by 
means of FMT without describing the complex 
debate as to whether this organism is a true en-
teropathogen. 
In developed countries, blastocystis is detect-
able in more than 50% of healthy persons with 
the use of polymerase-chain-reaction–based as-
says.2 No difference in the prevalence of blasto-
cystis exists between hosts with gastrointestinal 
symptoms and those without such symptoms,3 
and symptoms that are attributed to blastocystis 
infection may not improve even after the elimi-
nation of the organism.4 The organism has been 
shown to be capable of both long-term coloniza-
tion2 and spontaneous disappearance without 
intervention.4,5 Physicians offering FMT should 
carefully monitor FMT recipients for infectious 
complications but must be aware that presence 
is not the same as causation.
Benjamin H. Mullish, M.B., B.Chir.
Imperial College London 
London, United Kingdom 
b.mullish@imperial.ac.uk
No potential conflict of interest relevant to this letter was re-
ported.
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The Discussant Replies: We understand the 
controversy surrounding B. hominis (an anaerobic 
protozoan), and the case referenced in the dis-
cussion, reported by a Canadian physician, high-
lights it nicely. The patient had recurrent Clostrid-
ium difficile infection, and the spousal donor, who 
had no gastrointestinal symptoms, had stool that 
tested positive for B. hominis (no other donor was 
readily available). The FMT cured the C. difficile 
infection, but intermittent loose stools lasting 
months subsequently developed, with positive 
tests for blastocystis. A course of nitazoxanide 
cured the symptoms. 
At a recent American Gastroenterological As-
sociation conference on FMT, physicians noted 
that blastocystis was a common finding in do-
nor stool specimens (e.g., in 6 of 38 specimens 
that were screened in an Australian study).1 The 
consensus of practitioners was that it would not 
be advisable to use such specimens for FMT. At-
tendees did not mention other cases of trans-
mission of infectious agents by FMT. Represen-
tatives of the Food and Drug Administration 
highlighted the possibility of transmission of 
currently unknown infectious agents and the 
need for judicious use and careful follow-up of 
recipients of FMT.
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